» Articles » PMID: 10923640

Plasminogen Activator Inhibitor 1, Transforming Growth Factor-beta1, and BMI Are Closely Associated in Human Adipose Tissue During Morbid Obesity

Overview
Journal Diabetes
Specialty Endocrinology
Date 2000 Aug 3
PMID 10923640
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

In adipose tissue from both obese mice and humans, plasminogen activator inhibitor 1 (PAI-1) expression has been reported to be upregulated to levels of increased plasma PAI-1. This elevated expression has been shown to be partly controlled by tumor necrosis factor (TNF)-alpha in mice. In humans, increased PAI-1 expression is associated with insulin resistance characterized by visceral fat accumulation. Therefore, the aim of this study was to investigate the expression pattern of PAI-1 and TNF-alpha (antigen and mRNA) in visceral human adipose fat in comparison with subcutaneous (SC) fat. Because transforming growth factor (TGF)-beta1 is a potent inducer of PAI-1 synthesis and has been shown to influence adipocyte metabolism, this work was extended to TGF-beta1 quantification. A total of 32 obese individuals (BMI 42 +/- 6.8 kg/m2) were investigated. Freshly collected visceral adipose tissue did not exhibit a higher content of PAI-1 or TGF-beta1 than did SC tissue. Although most of the TNF-alpha values were at the detection limit of the methods, TNF-alpha antigen was 3-fold higher and TNF-alpha mRNA was 1.2-fold higher in visceral fat. The levels of tissue TGF-beta1 antigen correlated well with those of PAI-1 antigen, regardless of the fat depot studied (SC tissue: n = 21, r = 0.72, P = 0.0006; visceral tissue: n = 20, r = 0.49, P < 0.03), and they were both significantly associated with BMI. Conversely, no relationship was observed between the levels of TNF-alpha and PAI-1 or TNF-alpha and BMI. Tissue PAI-1 levels were also significantly correlated with those of circulating PAI-1. These results describe, in severe obesity, a proportional increase in tissue PAI-1 and TGF-beta1 in visceral and SC tissues. This increased PAI-1 expression could be the result of tissue cytokine disturbances, such as elevated TGF-beta1 expression.

Citing Articles

A Novel Injectable Polypeptide Nanoparticle Encapsulated siRNA Targeting TGF-β1 and COX-2 for Localized Fat Reduction II: Phase I Clinical Trial.

Nestor M, Hetzel J, Awad N, Bhupalam V, Lu P, Molyneaux M J Cosmet Dermatol. 2024; 24(2):e16722.

PMID: 39692702 PMC: 11845920. DOI: 10.1111/jocd.16722.


A possible role of plasmin-dependent activation of TGF-β in cancer-associated thrombosis: Implications for therapy.

Smeda M, Maleki E, Jasztal A Cancer Metastasis Rev. 2024; 44(1):2.

PMID: 39576347 PMC: 11584501. DOI: 10.1007/s10555-024-10222-6.


Association of Obesity and Severe Asthma in Adults.

Olejnik A, Kuznar-Kaminska B J Clin Med. 2024; 13(12).

PMID: 38930006 PMC: 11204497. DOI: 10.3390/jcm13123474.


The blockade of the TGF-β pathway alleviates abnormal glucose and lipid metabolism of lipodystrophy not obesity.

Xu W, Lai S, Zhao J, Wei S, Fang X, Liu Y Pharmacol Res Perspect. 2024; 12(1):e1160.

PMID: 38174807 PMC: 10765454. DOI: 10.1002/prp2.1160.


Thrombospondin1 antagonist peptide treatment attenuates obesity-associated chronic inflammation and metabolic disorders in a diet-induced obese mouse model.

Zhou Q, Gwag T, Wang S Sci Rep. 2023; 13(1):20193.

PMID: 37980376 PMC: 10657402. DOI: 10.1038/s41598-023-47635-2.